PRA Health Sciences (PRAH) Shares Sold by Jane Street Group LLC

Jane Street Group LLC trimmed its stake in PRA Health Sciences (NASDAQ:PRAH) by 40.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 3,342 shares of the medical research company’s stock after selling 2,256 shares during the period. Jane Street Group LLC’s holdings in PRA Health Sciences were worth $304,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Jennison Associates LLC raised its stake in shares of PRA Health Sciences by 238.6% in the 4th quarter. Jennison Associates LLC now owns 11,202 shares of the medical research company’s stock valued at $1,020,000 after acquiring an additional 7,894 shares during the period. Fox Run Management L.L.C. purchased a new stake in shares of PRA Health Sciences in the 4th quarter valued at approximately $439,000. Virtu Financial LLC purchased a new stake in shares of PRA Health Sciences in the 4th quarter valued at approximately $401,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of PRA Health Sciences by 82.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,069 shares of the medical research company’s stock valued at $279,000 after acquiring an additional 1,388 shares during the period. Finally, Fagan Associates Inc. purchased a new stake in shares of PRA Health Sciences in the 4th quarter valued at approximately $1,280,000. 99.22% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

In related news, VP Linda Baddour sold 67,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $90.27, for a total transaction of $6,048,090.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 2.10% of the stock is owned by corporate insiders.

A number of research firms have recently issued reports on PRAH. Zacks Investment Research raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating and set a $103.00 price target on the stock in a research note on Thursday, January 11th. BidaskClub downgraded shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 2nd. Credit Suisse Group reissued an “outperform” rating and issued a $104.00 price target (up from $101.00) on shares of PRA Health Sciences in a research note on Thursday, February 22nd. KeyCorp reissued a “buy” rating and issued a $100.00 price target on shares of PRA Health Sciences in a research note on Wednesday, January 31st. Finally, Mizuho downgraded shares of PRA Health Sciences from a “buy” rating to a “neutral” rating and set a $86.00 price target on the stock. in a research note on Wednesday, January 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. PRA Health Sciences currently has an average rating of “Buy” and a consensus target price of $95.67.

Shares of PRAH opened at $87.00 on Monday. PRA Health Sciences has a fifty-two week low of $61.93 and a fifty-two week high of $95.90. The company has a market cap of $5,512.17, a P/E ratio of 27.19, a price-to-earnings-growth ratio of 1.38 and a beta of 0.49. The company has a current ratio of 0.90, a quick ratio of 0.90 and a debt-to-equity ratio of 1.31.

PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Wednesday, February 21st. The medical research company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.02. PRA Health Sciences had a net margin of 3.85% and a return on equity of 22.77%. The firm had revenue of $568.80 million for the quarter, compared to the consensus estimate of $543.78 million. During the same period in the prior year, the firm earned $0.71 EPS. The firm’s revenue for the quarter was up 37.5% on a year-over-year basis. research analysts forecast that PRA Health Sciences will post 3.81 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2018/04/16/pra-health-sciences-prah-shares-sold-by-jane-street-group-llc.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply